Temporal Evolution of the Impact of CKD on COVID-19 Outcomes: A Five-Year Nationwide Analysis
Kidney360 · 2026
DOI: 10.34067/kid.0000001133 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney360, 2026. Verfasst von José D González-Barajas und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Civil de Oriente, Tónala, Mexico. Hauptthemen laut MEDLINE: COVID-19, Renal Insufficiency, Chronic. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
CKD is among the strongest predictors of adverse COVID-19 outcomes, yet how CKD-associated risk evolved across pre-vaccination, roll-out, mass-vaccination, and post-pandemic phases remains incompletely defined in Latin America.
Methods
We performed a nationwide retrospective analysis of Mexico’s historical surveillance open datasets, including all laboratory-confirmed cases from January 1, 2020 to June 30, 2025. The primary outcome was death among recorded cases (case-fatality); secondary outcomes were hospitalization, ICU admission, and invasive mechanical ventilation (IMV). Multivariable logistic models were fit overall, by age strata and year/pandemic phase, adjusting for demographics, comorbidities, and symptom-to-care interval; temporal patterns were summarized with LOESS and segmented interrupted time-series analysis. Sensitivity analyses included models restricted to ICU admissions and models additionally adjusted for municipal socioeconomic context.
Results
Among 7,359,354 cases, 70,144 (1.0%) had CKD; crude case-fatality was 33% in CKD vs 4% without. In adjusted models, CKD was associated with higher case-fatality (aOR 1.20, 95% CI 1.19–1.20) and hospitalization (aOR 1.35, 95% CI 1.35–1.35), but not with ICU admission (aOR 0.98) or IMV (0.99). In the ICU-restricted cohort, CKD independently increased in-ICU case-fatality (aOR 1.38, 95% CI 1.25–1.51), strongest at ages 18–64 (aOR 1.52) and smaller at ≥65 (aOR 1.19). Year-specific models showed attenuation during mass vaccination (2022 aOR 1.13) followed by a resurgence in 2024 (aOR 1.90). LOESS/ITS revealed delayed and incomplete post-vaccination benefit for CKD with trend acceleration in 2023. Findings were robust after adding municipal SES indicators to adult models.
Conclusions
Across five years of nationwide surveillance, CKD remained a dominant, independent correlate of COVID-19 case-fatality and hospitalization, with risk resurging in 2024. Lower ICU/IMV use yet higher in-ICU case-fatality among CKD patients may reflect selection effects and underscore the need for rapid escalation pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hospital Civil de Oriente, Tónala, Mexico.
- Centro Universitario de Tlajomulco, Universidad de Guadalajara, Tlajomulco de Zúñiga, Mexico.
ORCID-Profile: José D González-Barajas, Carolina Romo-Alvarez
Zitieren
APA
González-Barajas, J. D., Prieto-Magallanes, M. L., Romo-Alvarez, C., Díaz-Villavicencio, B., Camarena-Arteaga, V. A., López-Yáñez, A. M., De Arcos-Jiménez, J. C., & Briseno-Ramirez, J. (2026). Temporal Evolution of the Impact of CKD on COVID-19 Outcomes: A Five-Year Nationwide Analysis. Kidney360. https://doi.org/10.34067/kid.0000001133
Vancouver
González-Barajas JD, Prieto-Magallanes ML, Romo-Alvarez C, Díaz-Villavicencio B, Camarena-Arteaga VA, López-Yáñez AM, et al. Temporal Evolution of the Impact of CKD on COVID-19 Outcomes: A Five-Year Nationwide Analysis. Kidney360. 2026. doi:10.34067/kid.0000001133
BibTeX
@article{GonzlezBarajas2026,
author = {González-Barajas, José D and Prieto-Magallanes, Manuel L and Romo-Alvarez, Carolina and Díaz-Villavicencio, Bladimir and Camarena-Arteaga, Violeta A and López-Yáñez, Ana M and De Arcos-Jiménez, Judith C and Briseno-Ramirez, Jaime},
title = {Temporal Evolution of the Impact of CKD on COVID-19 Outcomes: A Five-Year Nationwide Analysis},
journal = {Kidney360},
year = {2026},
doi = {10.34067/kid.0000001133}
}
EUVIMED